VolitionRx develops easy to use blood-based cancer tests to accurately diagnose a range of cancers.
VolitionRx has raised $4.6M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
VolitionRx's investors include WE International, Namur Invest.
VolitionRx is headquartered in Henderson, United States.
VolitionRx develops easy to use blood-based cancer tests to accurately diagnose a range of cancers.
VolitionRx is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VolitionRx — Funding & Investors." VCBacked, June 7, 2026, https://www.vcbacked.co/company/volitionrx. Accessed October 2, 2026.
VCBacked. (2026). VolitionRx — Funding & Investors. Retrieved October 2, 2026, from https://www.vcbacked.co/company/volitionrx
{{cite web |title=VolitionRx — Funding & Investors |url=https://www.vcbacked.co/company/volitionrx |website=VCBacked |access-date=October 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated